The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS

Am J Hematol. 2018 Sep;93(9):E220-E222. doi: 10.1002/ajh.25160. Epub 2018 Aug 6.

Authors

Satoko Oka¹, Kazuo Ono², Masaharu Nohgawa¹

Affiliations

¹ Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, Japan.
² Division of Pathology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.

No abstract available

Publication types

Letter

MeSH terms

Azacitidine / pharmacology*
Azacitidine / therapeutic use
Bone Marrow Examination
Disease Progression
Female
Humans
Interleukin-6 / genetics
Japan
Male
Monoclonal Gammopathy of Undetermined Significance / complications*
Monoclonal Gammopathy of Undetermined Significance / drug therapy*
Monoclonal Gammopathy of Undetermined Significance / genetics
Myelodysplastic Syndromes / complications
Myelodysplastic Syndromes / drug therapy*
Myeloma Proteins / drug effects*
Retrospective Studies
Tumor Suppressor Protein p53 / genetics

Substances

IL6 protein, human
Interleukin-6
Myeloma Proteins
TP53 protein, human
Tumor Suppressor Protein p53
multiple myeloma M-proteins
Azacitidine